Compelling evidence have demonstrated that bulk tumors can arise from a unique subset of
cells commonly termed “cancer stem cells” that has been proposed to be a strong driving …

Targeted protein degradation (TPD) technologies have catalyzed a paradigm shift in
therapeutic strategies and offer innovative avenues for drug design. Hydrophobic tags …

Metastatic tumors remain lethal due to primary/acquired resistance to therapy or cancer stem
cell (CSC)-mediated repopulation. We show that a fasting-mimicking diet (FMD) activates …

The enhancer of zeste homolog 2 (EZH2) is the main enzymatic subunit of the PRC2
complex, which catalyzes trimethylation of histone H3 lysine 27 (H3K27me3) to promote …

PALI1 is a newly identified accessory protein of the Polycomb repressive complex 2 (PRC2)
that catalyzes H3K27 methylation. However, the roles of PALI1 in cancer are yet to be …

Recently, despite the great success achieved by the so‐called “magic bullets” in the
treatment of different diseases through a marked and specific interaction with the target of …

EZH2 is usually overexpressed in TNBC and other tumors, which has a great influence on
the occurrence, development and prognosis of tumors. However, current EZH2 inhibitors …

The histone methyltransferase G9a is well-documented for its implication in neoplastic
growth. However, recent investigations have demonstrated a key involvement of this …

Immunotherapies are revolutionizing the clinical management of a wide range of cancers.
However, intrinsic or acquired unresponsiveness to immunotherapies does occur due to the …

Neuroblastoma is one of the commonest extra-cranial pediatric tumors, and accounts for
over 15% of all childhood cancer mortality. Risk stratification for children with neuroblastoma …